Franz B. Humer - 18 Jun 2025 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role: Director
Signature: Earl Douglas, Attorney-in-fact
Issuer symbol: ALLO
Transactions as of: 18 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 23 Jun 2025, 21:03:43 UTC
Previous filing: 09 Dec 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Humer Franz B	Director	210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO	Earl Douglas, Attorney-in-fact	20 Jun 2025	0001548072

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALLO	Restricted Stock Unit	Award	$0	+95,400		$0.000000	95,400	18 Jun 2025	Common Stock	95,400		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Mr. Humer has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company.

Content

Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Mr. Humer has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company.